NCT06983028Phase 2Recruiting

Atacicept in Multiple Glomerular Diseases

Study sponsor: Vera Therapeutics, Inc. · VERA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-11Estimated
Enrollment · participants250Estimated
Source updated2026-06-26Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Planned enrollment increased by 50 participants

Before: 200 participants (planned). After: 250 participants (planned).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview